Clinical Trials · NCT07817251
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 210
- Start date
- Sep 2026
- Locations
- 40 sites, United States
- Primary endpoint
- Number of treatment emergent adverse events (TEAEs)